Observational Study to Evaluate the Safety and Efficacy of NovoMix® 70 in Type 2 Diabetes

• Status: Completed
• Trial end date: 2008-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is conducted in Europe. The aim of this observational study is to evaluate the incidence of adverse events while using NovoMix® 70 under normal clinical practice conditions in Austria.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Biphasic Insulins; Insulin; Insulin Aspart

Criteria

Inclusion Criteria:

• Type 2 diabetes

• HbA1c over 7%

• No contraindication with NovoMix® 70

Exclusion Criteria:

• Type 1 diabetes

• Subjects participating in a clinical trial or another observational study

• Subjects under previous basis-bolus insulin therapy

• Women who are pregnant, breast feeding and women of child bearing capacity who are not using any reliable contraceptive method